Meeuwsen John A L, Wesseling Marian, Hoefer Imo E, de Jager Saskia C A
Laboratory for Experimental Cardiology, University Medical Center Utrecht, Utrecht, Netherlands.
Laboratory for Clinical Chemistry and Hematology, University Medical Center Utrecht, Utrecht, Netherlands.
Front Cardiovasc Med. 2017 Jul 14;4:44. doi: 10.3389/fcvm.2017.00044. eCollection 2017.
Atherosclerosis is a lipid driven chronic inflammatory disease underlying the majority of ischemic events such as myocardial infarction or stroke. Clinical management of ischemic events has improved considerably in the past decades. Accordingly, survival rates have increased. Nevertheless, 12% of patients die within 6 months after the initial event. To improve secondary prevention, appropriate risk prediction is key. However, up to date, there is no clinically available routine marker to identify patients at high risk for recurrent cardiovascular events. Due to the central role of inflammation in atherosclerotic lesion progression and destabilization, many studies have focused on the role of circulating inflammatory cells in these processes. This review summarizes the current evidence on the potential of circulating inflammatory cells as biomarkers for recurrent adverse manifestations in acute coronary syndrome and stable coronary artery disease patients.
动脉粥样硬化是一种由脂质驱动的慢性炎症性疾病，是大多数缺血性事件（如心肌梗死或中风）的基础。在过去几十年中，缺血性事件的临床管理有了显著改善。相应地，生存率有所提高。然而，12%的患者在初次事件后的6个月内死亡。为了改善二级预防，适当的风险预测是关键。然而，到目前为止，尚无临床上可用的常规标志物来识别有复发性心血管事件高风险的患者。由于炎症在动脉粥样硬化病变进展和不稳定中起核心作用，许多研究聚焦于循环炎症细胞在这些过程中的作用。本综述总结了关于循环炎症细胞作为急性冠状动脉综合征和稳定型冠状动脉疾病患者复发性不良表现生物标志物潜力的当前证据。
